Estradiol Transdermal Patch and Dehydroepiandrosterone: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Estradiol Transdermal Patch
Dehydroepiandrosterone
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased risk of estrogenic adverse effects
Interaction Deep Dive
Combining dehydroepiandrosterone (DHEA) with estrogen may result in symptoms of estrogen excess. DHEA has increased endogenous estrogen levels in postmenopausal women1. Pre- and post-menopausal women have effective enzymatic systems for the biotransformation of DHEA to C-19 and C-18 sex steroids 1, suggesting that increased estrogen levels may occur in all women regardless of menopausal status.
Why it happens (mechanism)
Additive estrogenic effect since dehydroepiandrosterone is enzymatically converted into C-19 and C-18 sex steroids
Literature reports
1 report — tap to read
a) Estrone and estradiol levels increased to two-times the basal value following four weeks of dehydroepiandrosterone (DHEA) 400 milligrams (mg) four times daily for 28 days in six postmenopausal women in a double-blind, placebo-controlled, crossover study. Subjects received DHEA or placebo for 28 days, followed by a 2-week washout period, then crossed over to the other treatment (DHEA or placebo). Estrone increased from 58.7 +/- 11.0 to 167.4 +/- 66.6 picomole/liter (pmol/L) and estradiol increased from 36.7 +/- 3.7 to 121.1 +/- 25.7 pmol/L. This corresponds to a maximal percent change of 214 +/- 67 percent and 181 +/- 29 percent for estrone and estradiol, respectively 1.
Common questions
Can I take Estradiol Transdermal Patch and Dehydroepiandrosterone together?
Increased risk of estrogenic adverse effects Always confirm with your pharmacist or prescriber before making any change.
How serious is the Estradiol Transdermal Patch and Dehydroepiandrosterone interaction?
It is rated minor. Usually limited clinical impact.
How quickly could this interaction happen?
The documented onset is "delayed". Effects tend to build up gradually over days to weeks.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Estradiol Transdermal Patch or Dehydroepiandrosterone need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there anything you'd monitor while I'm on both?
References (1)
- Mortola JF & Yen SSC: The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab 1990; 71(3):696-704. PubMed
Keep reading about Estradiol Transdermal Patch
Keep reading about Dehydroepiandrosterone
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist